# OnCo record medulloblastoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/medulloblastoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "medulloblastoma" ;
  schema:name "Medulloblastoma"@en ;
  schema:description "Medulloblastoma is the most common malignant childhood brain tumour, arising in the cerebellum. Surgery, radiation to the whole brain and spine, and chemotherapy cure about 70%, at a heavy cost to thinking and growth; treatment is now being tailored to four molecular subgroups so that the low-risk children get less."@en ;
  schema:url <https://onco.cc/cancers/medulloblastoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Medulloblastoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1333608> ;
  schema:citation <https://www.cancer.gov/types/brain/patient/child-medulloblastoma-treatment-pdq>, <https://doi.org/10.1007/s00401-011-0922-z>, <https://childrensoncologygroup.org/> ;
  onco:tag "gap-fill", "paediatric", "cns" ;
  onco:related <https://onco.cc/collections/national-brain-tumor-society/>, <https://onco.cc/cancers/atrt/>, <https://onco.cc/cancers/ependymoma/>, <https://onco.cc/cancers/cns-germ-cell-tumours/>, <https://onco.cc/cancers/glioblastoma/> ;
  onco:technologies <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/antineoplastons/> ;
  onco:targets <https://onco.cc/targets/smoothened/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/lomustine/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/drugs/carmustine/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:pathways <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:terms <https://onco.cc/terms/blood-brain-barrier/> ;
  onco:trials <https://onco.cc/trials/ccss/>, <https://onco.cc/trials/acns0332/> ;
  onco:pipeline <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/technologies/methylation-profiling/> ;
  onco:standardOfCare <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/lomustine/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/vismodegib/> .